Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$494.46 USD
-11.32 (-2.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $494.52 +0.06 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$494.46 USD
-11.32 (-2.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $494.52 +0.06 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum D VGM
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
by Zacks Equity Research
Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of -11.57% and 0.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
by Ekta Bagri
While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
by Ekta Bagri
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
BMY vs. VRTX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. VRTX: Which Stock Is the Better Value Option?
Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Ahan Chakraborty
Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Curious about Vertex (VRTX) Q2 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will the Fed Cut Rates and Make Stock Owners Happy?
by John Blank
Or is the event of a SEP rate cut 'all priced in'?
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $490.80, denoting a +0.1% change from the preceding trading day.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
by Zacks Equity Research
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.
Here's Why Vertex Pharmaceuticals (VRTX) Gained But Lagged the Market Today
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $495.91, indicating a +0.88% shift from the previous trading day.
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
by Ekta Bagri
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog ASML, SAP, Nvidia, Vertex and EssilorLuxxottica
by Zacks Equity Research
ASML, SAP, Nvidia, Vertex and EssilorLuxxottica are included in this Analyst Blog.
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $490.85, signifying a +0.43% move from its prior day's close.
A Big Week in the USA: Global Week Ahead
by John Blank
Inflation and higher rates have tested the resilience of households as signs of a cooling economy and inflation bolster expectations for rate cuts to start in September.
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Kinjel Shah
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Top Research Reports for Exxon Mobil, Merck & Qualcomm
by Santanu Roy
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Merck & Co., Inc. (MRK) and QUALCOMM Incorporated (QCOM), as well as two micro-cap stocks Armanino Foods of Distinction, Inc. (AMNF) and AMCON Distributing Company (DIT).
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $485.99, indicating a +0.85% shift from the previous trading day.